| Name | Title | Contact Details |
|---|
The Alaska Native Tribal Health Consortium is a not-for-profit tribal health organization managed by Alaska Native tribal governments and their regional health organizations.
Affymetrix/USB Corporation is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation that develops and commercializes high-value cancer diagnostic tests that increase clinician and patient confidence in making critical treatment decisions. In 2008, the Corporation launched a colorectal cancer staging test through its U.S. CLIA laboratory. PrevistageTM GCC is currently available for licensing. The Corporation has granted a worldwide exclusive license on the diagnostic applications of its proprietary molecular biomarker PCA3 to Gen-Probe, now a wholly-owned subsidiary of Hologic Inc. Hologic Gen-Probe's PROGENSA® PCA3 prostate cancer test is commercialized in Europe under CE mark and is approved for commercialization in Canada and the United States.
Private Healthcare Systems Inc. is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Rally® believes in putting health care in the hands of individuals with a seamless experience, providing personalized, data-driven information and recommendations that can help improve outcomes and decrease costs for everyone. Rallys Health Solutions help members set personalized daily goals, gives recommendations, and incentivizes progress with rewards. Rallys Care Solutions make health benefits easy to understand and care easy to find on the computer or the Rally app. More than 20 million consumers currently have access to the Rally platform through payers such as UnitedHealthcare, BlueCross BlueShield of South Carolina, and thousands of employer groups. Across offices in Washington, D.C., San Francisco, Chicago, Minneapolis, Denver, and Las Vegas, Rallyers have dedicated themselves to transforming the health care industry for the better—Together.